Key Highlights

  • Eli Lilly (NYSE:LLY) reports before the open on Thursday, October 29, 2026, with consensus earnings per share of USD 5.38, making it the largest healthcare event on the calendar.
  • Merck, Bristol Myers Squibb and Altria report alongside Eli Lilly before the bell, with consensus EPS of USD 2.12, USD 1.28 and USD 1.51, so the sector read-through arrives together.
  • The USD 5.38 figure comes from one earnings calendar page; revenue, obesity-drug and guidance expectations were not retrieved, so this is a preview, not a results article.
  • Eli Lilly (NYSE:LLY) reports the same morning as September PCE inflation and third-quarter GDP at 7:30 a.m. ET, with December Fed hike odds near 81% to 85%.

What Is Scheduled for October 29

Eli Lilly (NYSE:LLY) is scheduled to report before the open on Thursday, October 29, 2026, and one published earnings calendar shows consensus earnings per share of USD 5.38. Three other large names report before the bell. Merck (NYSE:MRK) carries a consensus of USD 2.12. Bristol Myers Squibb (NYSE:BMY) is at USD 1.28. Altria (NYSE:MO) is at USD 1.51. Results were not out when this was written, and the consensus numbers come from a single calendar page that did not include revenue, obesity-drug or guidance expectations, so treat them as a starting point rather than a verified Street model. Nothing in this preview should be read as an expectation of a beat or miss.

How an Earnings Reaction Works

Consensus earnings per share is the average of analyst estimates, and a stock rarely moves on that number alone. For a large drugmaker, the reaction usually depends on revenue against expectations, product-level sales and whether management raises, holds or trims full-year guidance. A company can beat on earnings per share and still fall if guidance disappoints, because the share price already reflects what investors expect. That is why the missing obesity-drug and guidance expectations matter: without them, a headline beat or miss against USD 5.38 is only part of the picture, and Eli Lilly (NYSE:LLY) has no single-line verdict until the company release is out. Any move in the shares will depend on commentary as much as on the figures themselves.

Risks and What to Watch Next

The macro backdrop adds noise. The Federal Reserve held at 3.75% to 4.00% on October 28, and published market data show roughly 81% to 85% odds of a December hike, with sources differing on the exact figure. The 10-year Treasury yield closed above 5% on October 28, which raises the rate used to discount future earnings. A hot PCE print at 7:30 a.m. ET could pressure growth stocks regardless of company results. The company-specific risks are a guidance cut or a revenue miss. Nasdaq-100 futures were down about 1.2% before 4:30 a.m. ET, so the open may be volatile. Traders should also expect options pricing to reflect a sizeable move.

Where Things Stand

Eli Lilly (NYSE:LLY) is the day's biggest healthcare event because it is the largest name reporting on a crowded morning, but how the day is remembered will depend on guidance, not just the USD 5.38 consensus. The evidence cannot be settled before the release: the earnings figure rests on one calendar page, and revenue and obesity-drug expectations were not retrieved. The next catalyst is the company release itself, followed by Merck, Bristol Myers Squibb and Altria the same morning.